Circassia Puts Aside R&D, Aims To Grow Commercial Platform
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.
UK biotech Circassia puts Phase III cat allergy vaccine failure behind it and intends to move forward with building its commercial platform, and sales, in the respiratory sector.